Epstein-Barr Virus Causes Nasopharyngeal Cancer and Lymphomas

In addition to its original linkages with Burkitt's lymphoma and infectious mononucleosis, Epstein-Barr virus is now believed to be the cause of nasopharyngeal carcinoma, T-cell and natural killer (NK) cell lymphomas, and Hodgkin's disease, and is also implicated in gastric carcinomas and lymphoepithelioma-like lung cancer. As usual, the anti-smokers ignore the role of this virus in order to falsely blame smoking and passive smoking.

EBV has been declared a Class I human carcinogen by the IARC. (Epstein Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans). IARC Monograph 70. Lyon: International Agency for Research on Cancer; 1997.)

"5.5 Evaluation. There is sufficient evidence for the carcinogenicity of EBV in the causation of Burkitt's lymphoma, sinonasal angiocentric T-cell lymphoma, immunosuppression-related lymphoma, Hodgkin's disease and nasopharyngeal carcinoma."

"EBV is carcinogenic to humans (Group I)."

Review

Epstein-Barr Virus and Cancer. MP Thompson, R Kurzrock. Clinical Cancer Research 2004 Feb;10(3):803-821. Review. "The EBV genomes present in the epithelial cells of the nasopharynx are of clonal origin, and EBV is absent from surrounding tissues and invading T lymphocytes. EBV has also been detected in in situ nasopharyngeal carcinoma, a precursor of undifferentiated nasopharyngeal carcinoma. These findings suggest that EBV infection occurs before neoplasia and is necessary for the progression of the malignant phenotype."

Other reviews

Epstein-Barr virus, infectious mononucleosis, Burkitt's lymphoma and nasopharyngeal carcinoma. G Klein. Israel J Med Sci 1977 Jul;13(7):716-724. "The timing and extent of seroconversion are strongly related to socioeconomic status. In low socioeconomic groups, infection occurs during early childhood, as a rule. It is not accompanied by any recognized disease, and the route of transmission is unknown. Only a minority of children become infected in high socioeconomic groups where a later infection, during the teens, predominates."

Epstein-Barr virus infecions and their association with human malignancies: some key questions. BE Griffin, SA Xue. Ann Med 1998 Jun;30(3):249-259. "Many questions partly addressed here remain with regard to this virus, two critical ones relating to the mechanisms by which viral gene products excape T-cell recognition -- relevant from the fact that gene expression is not tightly restricted to nonimmunogenic functions in tumours -- and whether EBV can invoke cell growth in a manner not requiring its continued presence. The latter seems a plausible hypothesis and is of particular importance with regard to identifying and understanding pathologies associated with EBV, as viral transcription transactivators may on initial infection permanently perturb cell regulation."

Epstein-Barr virus: the first human tumor virus and its role in cancer. JS Pagano. Proc Assoc Am Physicians 1999 Nov-Dec;111(6):573-580. "The relation of the virus to the malignancies varies from primary etiologic agent to necessary or contributory co-factor.... Most of the malignancies occur after years of viral dormancy and are accompanied or triggered by viral reactivation, in contrast to infectious mononucleosis, which results from primary infection with EBV."

Epstein-Barr virus-associated diseases in humans. K Kawa. Int J Hematol 2000 Feb;71(2):108-117. Review.

Haematological associations of Epstein-Barr virus infection. M Okano. Baillieres Best Pract Res Clin Haematol 2000 Jun;13(2):199-214.

Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. GJ Babcock, DA Thorley-Lawson. Proc Natl Acad Sci 2000 Oct 24;97(22): 12250-12255.

The role of epstein-barr virus in neoplastic transformation. H Knecht, C Berger, S Rothenberger, BF Odermatt, P Brousset. Oncology 2001;60(4):289-302. Review.

Epstein-Barr virus (EBV) and human disease: facts, opinions and problems. BE Griffin. Mutat Res 2000 Apr;462(2-3):395-405. Review. "We also consider tumours where the viral association is reportedly of low frequency, and offer explanations for these data, including the possibility of the loss of the viral genome once malignancy has been initiated. If this phenomenon occurs as a frequent secondary event, EBV could be an even greater health risk than presently believed."

EBV in Nasopharyngeal Carcinoma

Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. LJ Old, EA Boyse, HF Oettgen, ED Harven, G Geering, B Williamson, P Clifford. Proc Natl Acad Sci U S A 1966 Dec;56(6):1699-1704. 19 of 20 (95%) sera of patients with carcinoma of the postnasal space were positive to an antigen prepared from cultured Burkitt's lymphoma cells.

Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. W Henle, G Henle, HC Ho, P Burtin, Y Cachin, P Clifford, A de Schryver, G de-The, V Diehl, G Klein. J Natl Cancer Inst 1970 Jan;44(1):225-231. "Of 235 East African and Chinese patients who were classified as cases of nasopharyngeal carcinoma (NPC), 84% had high anti-EBV titers," and the histopathology "seemed irrelevant." Antibody levels increased according to stage.

Antibodies to Epstein-Barr virus in nasopharyngeal cancer and other neoplastic conditions. SD Kottaridis, M Dafnou, S Besbeas, J Garas. J Natl Cancer Inst 1977 Jul;59(1):89-91. "The data reaffirmed the association of EBV with NPC."

Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. M Andersson-Anvret, N Forsby, G Klein, W Henle. Int J Cancer 1977 Oct 15;20(4):486-494. "a correlated histopathological and nucleic acid hybridization study was performed on 51 undifferentiated NPC, 4 NPC with some signs of squamous differentiation, 7 nasophayngeal tumors of other histological types and 14 head and neck carcinomas located outside the nasopharynx. All 51 undifferentiated NPCs contained significant numbers of EBV-genome copies per cell. Two of the somewhat differentiated NPCs were also EBV-DNA-positive, whereas 2 were negative. Of the 7 other nasopharyngeal tumors, 1 was EBV-DNA-positive. Histological examination, however, showed that this was a typical Burkitt lymphoma. The other 6 tumors were all EBV-DNA-negative lymphoproliferative malignancies. All 14 had head and neck carcinomas located outside the nasopharynx were EBV-DNA-negative. The sera of undifferentiated NPC patients had elevated antibody titers against the EBV-determined antigens, the EA (D) componet in particular. These findings confirm that there is a regular association between EBV-DNA and undifferentiated NPC."

Human nasopharyngeal carcinomas positive for Epstein-Barr virus DNA in North America. R Glaser, M Nonoyama, RT Szymanowski, W Graham. J Natl Cancer Inst 1980 Jun;64(6):1317-1319. "Nasopharyngeal carcinomas (NPC) from 2 black patients and 1 Caucasian patient were positive for Epstein-Barr virus (EBV) DNA. Of the tumors, 2 were lymphoepitheliomas (undifferentiated NPC) and 1 was a moderately differentiated NPC. All 3 patients had high IgG titers against EBV early antigen and high IgG and IgA titers against virus capsid antigen (VCA). In one patient, the levels of anti-VCA IgA were different than those of anti-VCA IgG over the course of the disease. Our data support the association of EBV and NPC in North America."

Nasopharyngeal cancer in Alaskan Eskimos, Indians, and Aleuts: A review of cases and study of Epstein-Barr virus, HLA, and environmental risk factors. A Lanier, T Bender, M Talbot, S Wilmeth, C Tschopp, W Henle, G Henle, D Ritter, P Terasaki. Cancer 1980 Nov 1;46(9):2100-2106. In 25 males and 6 females, "Antibodies to Epstein-Barr virus were higher in NPC patients than in patients with other tumors or matched controls.... In response to a questionnaire, NPC patients more often reported use of salt fish in the childhood diet, smoking of cigarettes, and exposure to noxious inhalants than did controls, but the differences were not statistically significant."

Anti-EBV serologic tests for nasopharyngeal carcinoma. HB Neel 3rd, GR Pearson, LH Welland, WF Taylor, HH Goepfert, BZ Pilch, AP Lanier, AT Huang, VJ Hyams, PH Levine, G Henle, W Henle. Laryngoscope 1980 Dec;90(12):1981-1990. In 63 American patients, "The level of antibody titers to EBV-associated antigens was correlated with nasopharyngeal carcinoma. The anti-EBV profile of elevated antibody titers directed against viral capsid antigen and early antigen was seen in undifferentiated and nonkeratinizing tumors but usually not in squamous cell tumors."

The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC). PH Levine, GR Pearson, M Armstrong, Z Bengali, J Berenberg, J Easton, H Goepfert, G Henle, W Henle, D Heffner, A Huang, VJ Hyams, A Lanier, HB Neel, B Pilch, N Pointek, W Taylor, H Terebolo, L Weiland. Cancer Detect Prev 1981;4(1-4):307-312. "The prospective study showed a relationship between IgA antibody titers and histopathology but not disease stage. IgA antibody titers were elevated more frequently in patients with nonkeratinizing or poorly differentiated types of NPC than for the well-differentiated squamous cell carcinomas. While IgA antibodies to EBV VCA appear to be of value in the early detection and diagnosis of NPC, it is possible that additional serologic tests for immunity to EBV, such as IgG antibody to VCA or early antigen (EA), will improve even further the clinical value of EBV serology in the management of NPC."

Association of Epstein-Barr virus with nasopharyngeal carcinoma in Alaskan native patients: serum antibodies and tissue EBNA and DNA. AP Lanier, GW Bornkamm, W Henle, G Henle, TR Bender, ML Talbot, PH Dohan. Int J Cancer 1981 Sep 15;28(3):301-305. "EBV DNA and EBNA results were in agreement in 29 of 31 tissue specimens tested by the two methods." 10/11 NPC biopsies were EBV+, as were 2 atypical epithelium biopsies, which were 1 lymphoepithelial lesion of the parotid gland and 1 undifferentiated salivary gland carcinoma.

Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. GR Pearson, LH Weiland, HB Neel 3rd, W Taylor, J Earle, SE Mulroney, H Goepfert, A Lanier, ML Talvot, B Pilch, M Goodman, A Huang, PH Levine, V Hyams, E Moran, G Henle, W Henle. Cancer 1983 Jan 15;51(2):260-268. "The results suggest that certain anti-EBV antibodies are of potential value for the diagnosis of undifferentiated types of NPC but not for the well-differentiated cancer. The IgA anti-VCA antibody response is the most specific for this disease and of the greatest diagnostic value when used alone or in combination with the anti-EA test. These tests have also been used successfully for the detection of occult NPC. These results indicate that these tests can be useful aids to the clinician for the diagnosis of certain histopathologic types of this disease."

Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. HB Neel 3rd, GR Pearson, LH Weiland, WF Taylor, HH Goepfert, BZ Pilch, M Goodman, AP Lanier, AT Huang, VJ Hyams, PH Levine, G Henle, W Henle. Otolaryngol Head Neck Surg 1983 Jun;91(3):255-262. "From 1978 to 1981, 151 patients with nasopharyngeal carcinoma (NPC) were enrolled in a prospective, collaborative study of North American patients, most of them white. Thirty-seven had World Health Organization (WHO) type 1 tumors, and 114 had WHO types 2 and 3 tumors. The anti-Epstein-Barr virus (EBV) profile of elevated antibody titers directed against viral capsid antigen and early antigen was seen in 85% of the patients with WHO types 2 and 3 tumors but in only 16% of the patients with WHO type 1 tumors."

Epstein-Barr virus antibody titers in cancer of the head and neck. DJ Callaghan, BR Connor, M Strauss. Arch Otolaryngol 1983 Dec;109(12):781-784. "Pretreatment serum samples from 39 white American patients with epidermoid cancer of various sites of the head and neck, including the nasopharynx, were studied for both IgA and IgG antibodies to the Epstein-Barr virus (EBV)-specific antigens. Of the various serological assays, IgG anti-viral capsid antigen (VCA) was least specific and was present frequently at high titers in both the groups with nasopharyngeal carcinoma (NPC) and groups with other cancers (OC). The geometric mean titer (GMT) of IgA anti-VCA was significantly elevated in patients with NPC compared with the groups with OC. The incidence of this virologic parameter was high in the laryngeal and stage III and IV oral cavity groups of epidermoid cancer, and the GMTs were significantly greater than the control group. Finally, the GMTs of all the antibodies to the EBV-associated antigens were significantly elevated in patients with NPC who had regional metastases compared with those who had local disease with cranial nerve involvement."

Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma. R Cevenini, M Donati, U Caliceti, A Moroni, I Tamba, F Rumpianesi. J Infect 1986 Mar;12(2):127-131. Confiming the association of EBV with NPC. "An association of Epstein-Barr virus (EBV) with nasopharyngeal carcinoma (NPC) has been established serologically in Italian patients. The finding of IgA antibodies to EBV-capsid antigen (VCA) and to early antigen (EA) showed a high degree of correlation for patients with NPC, thereby confirming previous reports. In addition, when considered together, IgA anti-VCA and IgG anti-EA antibody titres appeared to distinguish NPC-patients from those in control populations. Poorly differentiated and undifferentiated carcinomas with lymphoid cellular infiltrations showed the highest frequency of association with positive EBV serological tests."

Epstein-Barr virus seroepidemiology in China. Y Zeng, GH Pi, H Deng, JM Zhang, PC Wang, H Wolf, G De The. AIDS Res 1986 Dec;2 Suppl 1:S7-S15. In a prospective study of EBV positivity and nasopharyngeal cancer in 20,726 people, 1,138 had IgA VCA antibody. 18 NPC cases were found in these, and 21 more during five years of follow-up. "The detection rate of NPC from IgA VCA antibody-positive persons is 38-374 times the incidence rate of NPC in the general population of the same age group... No NPC patients were found in the original antibody negative group" [emphasis added].

The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. N Raab-Traub, K Flynn, G Pearson, A Huang, P Levine, A Lanier, J Pagano. Int J Cancer 1987 Jan 15;39(1):25-29. "24 undifferentiated and 4 partially differentiated specimens generally contained a relatively high number of EBV genome equivalents, while the 5 well-differentiated NPC all contained detectable EBV, but at low copy number... These findings indicate that all histologic subsets of NPC contain EBV DNA" [emphasis added].

Serological and immunohistochemical assessment of Epstein-Barr virus infection in Sicilian patients with suspected nasopharyngeal carcinoma. P Ammatuna, G de The, R Speciale, F Sammartano, S Arista, G Zerillo. Microbiologica 1988 Apr;11(2):89-94. 8/9 NPC patients had high EBV antibody levels; and 1/4 without NPC but with high antibody levels later developed NPC.

Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. R Fahraeus, HL Fu, I Ernberg, J Finke, M Rowe, G Klein, K Falk, E Nilsson, M Yadav, P Busson, et al. Int J Cancer 1988 Sep 15;42(3):329-338. "All 16 cases of clinically diagnosed and histologically confirmed NPCs from North Africa contained EBV DNA and expressed EBNA-1." 29/31 from China contained EBV DNA, and tumors from Malaysia and East Africa showed a similar pattern of expression.

Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency. C-J Chen, K-Y Liang, Y-S Chang, Y-F Wang, T Hsieh, M-W Hsu, J-Y Chen, M-Y Liu. Anticancer Res 1990 Mar;10(2B):547-553. The magic of multivariate analysis produces confounding again: "The older the age, the more striking the dose-response relation between cigarette smoking and NPC," where the causal factor EBV and the non-causal smoking are linked socioeconomically, and cohort effects produce further confusion, which contrary to pretenses, cannot be separated by statistical means.

Detection of Epstein-Barr virus DNA in formalin-fixed pariffin-embedded tissue of nasopharyngeal carcinoma using polymerase chain reaction and in situ hybridization. I Akao, Y Sato, K Mukai, H Uhara, S Furuya, T Hoshikawa, Y Shimosato, I Takeyama. Laryngoscope 1991 Mar;101(3):279-283. In Japanese patients, "Detection rates of Epstein-Barr virus in various types of nasopharyngeal carcinoma according to the World Health Organization classification were as follows: 10 of 10 undifferentiated carcinomas, 8 of 13 nonkeratinizing carcinomas, and 5 of 7 keratinizing carcinomas."

Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. L Brooks, Q Y Yao, A B Rickinson and L S Young. J Virol 1992 May;66(5):2689-2697. "All four transplantable NPC cell lines studied and 17 of 18 fresh snap-frozen NPC biopsy specimens expressed an EBNA1 mRNA with a BamHI Q/U/K splice structure exactly like that recently identified in group I Burkitt's lymphoma (BL) cell lines and shown to be driven from a novel viral promoter, Fp."

Herbal medicine use, Epstein-Barr virus, and risk of nasopharyngeal carcinoma. A Hildesheim, S West, E DeVeyra, MF De Guzman, A Jurado, C Jones, J Imai, Y Hinuma. Cancer Res 1992 Jun 1;52(11):3048-3051. 104 cases, 205 controls in The Philippines. "Subjects strongly positive for anti-EBV antibodies (Epstein-Barr nuclear antigen [EBNA]) (titers greater than or equal to 1:80) were at a 21-fold excess risk of disease (95% confidence interval, 8.4, 51.8).... Exposure to herbal medicines among subjects testing negative/weakly positive for anti-EBNA antibodies was not associated with an elevation in risk (relative risk, 0.6), strong positivity to anti-EBNA antibodies in the absence of herbal medicine use was associated with a significant 16-fold excess risk of disease, and exposure to herbal medicines among subjects testing strongly positive for anti-EBNA antibodies was associated with a significant 49-fold excess risk of NPC when cases were compared to controls."

Nasopharyngeal carcinoma: histopathological types and association with Epstein-Barr virus. U Hording, HW Nielsen, H Albeck, S Daugaard. Eur J Cancer B Oral Oncol 1993 Apr;29B(2):137-139. 23/23 nonkeratinizing and undifferentiated, and 2/14 keratinizing NPCs were positive for EBV genomic sequences.

Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. X Zheng, L Yan, B Nilsson, G Eklund, B Drettner B. Acta Oncol 1994;33(8):867-872. 205 cases in south China. "Multivariate analyses showed that IgA/VCA was the most important predictor of NPC, and salted fish the second most important. These results suggest that EBV has a strong effect on the development of NPC. The exclusion of EBV and genetic factors in earlier epidemiological studies may have resulted in an overestimation of salted fish as important etiological factor causing NPC."

[The value of polymerase chain reaction on Epstein-Barr virus subtypes in the differentiation of benign and malignant nasopharyngeal biopsies]. N Sun, X Chen. Zhonghua Er Bi Yan Hou Ke Za Zhi 1995;30(4):213-215. A proportion of patients with chronic nasopharyngitis are also positive for EBV by PCR.

Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. R Pathmanathan, U Prasad, G Chandrika, R Sadler, K Flynn, N Raab-Traub. Am J Pathol 1995 Jun;146(6):1355-1367. "Nasopharyngeal carcinoma (NPC) samples of distinct histological types, including squamous cell carcinoma (WHO type 1), nonkeratinizing carcinoma (WHO type 2), and undifferentiated carcinoma (WHO type 3), were analyzed for Epstein-Barr virus (EBV) infection and gene expression by using in situ and biochemical techniques. The EBV-encoded RNAs (EBER) were detected in situ in most tumor cells of all three WHO types of NPC. In foci of squamous differentiation and keratinization within less differentiated NPC and throughout the expanse of well differentiated squamous cell carcinoma, EBER expression was less abundant. Latent membrane protein, an EBV-encoded membrane protein, was detected in 72% (36/50) of all NPC and 67% (6/9) of the cases of squamous cell carcinoma. The EBV genomes were present as clonal episomal forms, without detectable linear viral DNA, in all cases of squamous cell carcinoma analyzed. Polymerase chain reaction amplification of cDNA detected EBV transcription for Epstein-Barr nuclear antigen 1, latent membrane proteins 1 and 2, and BamHI A in all samples, indicating that all forms of NPC express the same EBV genes. These results reveal that EBER expression is significantly decreased in areas with squamous differentiation and confirm that all types of NPC, regardless of histological type or differentiation contain clonal episomal EBV genomes, express specific EBV genes and are a clonal expansion of EBV-infected cells."

Detection of Epstein-Barr virus genome in sinonasal undifferentiated carcinoma by use of in situ hybridization. O Gallo, S Di Lollo, P Graziani, E Gallina, G Baroni. Otolaryngol Head Neck Surg 1995 Jun;112(6):659-664. Epstein-Barr virus DNA was detected in 38% (5 of 13) of nose and paranasal sinus carcinomas.

Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. R Pathmanathan, U Prasad, R Sadler, K Flynn, N Raab-Traub. N Engl J Med 1995 Sep 14;333(11):693-698. "Evidence of EBV infection was detected in all 11 tissue samples with dysplasia or carcinoma in situ. EBERs were identified in all eight samples tested, and LMP-1 was detected in all six of the tested samples. Six of the seven samples tested for the EBV termini contained clonal EBV DNA. Transcription of the latent EBV gene products, EBV nuclear antigen 1, LMP-1, LMP-2A, and the BamHI-A fragment, was detected in most of the samples. Viral proteins characteristic of lytic lesions were not detected. CONCLUSIONS. Preinvasive lesions of the nasopharynx are infected with EBV. The EBV DNA is clonal, indicating that the lesions represent a focal cellular growth that arose from a single EBV-infected cell and that EBV infection is an early, possibly initiating event in the development of nasopharyngeal carcinoma. Preinvasive lesions contain EBV RNAs that are characteristic of latent infection but not the viral proteins that are characteristic of lytic infection. The detection of the EBV-transforming gene, LMP-1, in all the neoplastic cells suggests that its expression is essential for preinvasive epithelial proliferations associated with nasopharyngeal carcinoma."

Epstein–Barr virus — Increasing evidence of a link to carcinoma. (Editorial re Pathmanathan.) E Kieff. N Engl J Med 1995 Sep 14;333(11):724-726.

Nasopharyngeal carcinoma: Epstein-Barr virus significance. SD Kottaridis, E Panotopoulos, I Diamantis, I Goula, J Danilidis, G Fountzilas. Anticancer Res 1996 Mar;16(2):785-789. In 31 NPCs, there was association with EBV; "no correlation between smoking and NPC was found."

Use of bacterially expressed GST/EBNA-1 fusion proteins for detection of antibodies in sera from patients with nasopharyngeal carcinoma and healthy donors. MR Chen, JF Yang, TY Hsu, MY Liu, JY Chen, CS Yang. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1996 May;29(2):65-79. All 38 NPCs were IgG positive for EBNA-1 in sera, versus only 2.6% of 38 healthy controls.

Enhanced malignant progression of nasopharyngeal carcinoma cells mediated by the expression of Epstein-Barr nuclear antigen 1 in vivo. LF Sheu, A Chen, CL Meng, KC Ho, WH Lee, FJ Leu, CF Chao. J Pathol 1996 Nov;180(3):243-248. "EBNA 1 caused HONE-1 cells to grow in a less differentiated pattern and to progress more rapidly, as well as increasing their tumourigenicity and metastatic capability."

Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. A Mutirangura, W Pornthanakasem, A Theambooniers, V Sriuranpong, P Lertsanguansinchi, S Yenrudi, N Voravud, P Supiyaphun, Y Poovorawan. Clin Cancer Res 1998 Mar;4(3):665-669. 13/42 NPC samples were EBV DNA-positive in sera, vs. 0/82 controls.

Comparative analysis of Epstein-Barr virus (EBV) detection by nested-PCR and non-isotopic in situ hybridization in nasopharyngeal carcinoma (NPC). F Vera-Sempere, J Burgos, MS Botella, C Morera. Clin Chim Acta 1998 Mar 23;271(2):119-132. In 54/55 cases with adequate quality DNA samples, "EBV-DNA was detected in 100% of cases using a nested-PCR, supporting the previous view that all histological types of NPC are in reality variants of EBV-infected neoplasia" [emphasis added].

Epstein-Barr virus detection in nasopharyngeal tissues of patients with suspected nasopharyngeal carcinoma. ST Tsai, YT Jin, RB Mann, RF Ambinder. Cancer 1998 Apr 15;82(8):1449-1453. 98.1% EBV+ by ISH. "In specimens from 107 patients with NPC, EBV was detected by PCR in 97 cases (90.7%) and by EBER in situ hybridization in 105 cases (98.1%). In specimens from 61 patients without neoplasia, EBV was detected by PCR in 7 cases (11.5%) and by EBER in situ hybridization in 0 cases."

Antibody against the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2, in patients with nasopharyngeal carcinoma. MY Liu, YY Shih, SP Chou, TS Sheen, CS Yang, JY Chen. J Med Virol 1998 Nov;56(3):179-185. "The demonstration of anti-BHRF1 antibody in most NPC sera strongly supports the hypothesis that the EBV BHRF1 protein is expressed in most NPC patients and its specific antibody can be a useful marker for the diagnosis of NPC."

Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction. R Punwaney, MS Brandwein, DY Zhang, ML Urken, R Cheng, CS Park, HB Li, X Li. Head Neck 1999 Jan;21(1):21-29. 30 patients (6 Caucasian Americans, 1 Chinese American, 14 and 9 patients from Korea and China). "Human papillomavirus appears to be uncommonly (17%) associated with NPC in patients from the Far East and was detected more often (50%) in NPC from American Caucasian patients." 5/6 Caucasian Americans were EBV-positive.

Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal cancer. YMD Lo, LYS Chan, K-W Lo, S-F Leung, J Zhang, ATC Chan, JCK Lee, NM Hjelm, PJ Johnson, DP Huang. Cancer Res 1999 Mar 15;59(6):1188-1191. 96% of 57 NPC patients and 7% of 43 control relatives were EBV+; disappearance of viral DNA corresponded with complete tumor regression.

Detection of human papilloma virus and Epstein-Barr virus DNA in nasopharyngeal carcinoma by polymerase chain reaction. YC Tung, KH Lin, PY Chu, CC Hsu, WR Kuo. Kao Hsiang I Hsueh Ko Hsueh Tsa Chih 1999 May;15(5):256-262. In 88 NPC tissue samples, "HPV and EBV DNA were detected in 51% and in 83% of the specimens, respectively. Coexistence of EBV and HPV in NPC was found in 42% of the samples. The "high risk" types including HPV-16 and HPV-18 accounted for 67% of 45 HPV positive samples. Furthermore, 80% of HPV-16 or HPV-18 positive samples also contained EBV DNA."

Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. TM Lo, LY Chan, SF Leung, KW Lo, J Zhang, JC Lee, NM Hjelm, PJ Johnson, DP Huang. Cancer Res 1999 Nov 1;59(21):5452-5455. Among 17 patients, "Continuous low or undetectable levels of serum EBV DNA were observed in the patients who remained in remission," versus a median of 32,350 copies/ml in relapsed patients.

Epstein-Barr virus strain characterisation in South African patients with nasopharyngeal carcinomas. E Janse van Rensburg, WF van Heerden, BA Robson, TJ Swart, S Engelbrecht. Anticancer Res 2000 May;20(3B):1953-1957. "EBV could be detected in 82% (31/38) of the tumours."

Association of Epstein-Barr virus (EBV) with nasopharyngeal carcinoma (NPC). SH Shah, IN Soomro, S Haroon, T Moatter. J Pak Med Assoc 2000 Jun;50(6):182-183. 6/17 were EBV+, marker not specified.

Epstein-Barr virus infection of sinonasal lymphoepithelial carcinoma in Guangzhou. Y Zong, K Liu, B Zhong, G Chen, W Wu. Chin Med J (Engl) 2001 Feb;114(2):132-136. "This tumor is also consistently associated with EBV infection like NPC" (20/20).

Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. JC Lin, KY Chen, WY Wang, JS Jan, WM Liang, CS Tsai, YH Wei. J Clin Oncol 2001 May 15;19(10):2607-2615; and: Distant metastases and poor prognoses indicated by Epstein-Barr virus DNA 1 in nasopharyngeal cancer. By Veronica Rose, Doctor's Guide News 2001 May 21.

Expression of Epstein-Barr virus-encoded RNA and biological markers in Italian nasopharyngeal carcinomas. E Gabusi, C Lattes, M Fiorentino, A D'Errico, WF Grigioni. J Exp Clin Cancer Res 2001 Sep;20(3):371-376. 23/26 (88%) of cases were positive for either EBER1, or bcl-2 protein or mRNA. "This study of NPC in Italy confirms the importance of EBV and bcl-2 in Western cases."

Occupational exposure to wood, formaldehyde, and solvents and risk of nasopharyngeal carcinoma. A Hildesheim, M Dosemeci, CC Chan, CJ Chen, YJ Cheng, MM Hsu, IH Chen, BF Mittl, B Sun, PH Levine, JY Chen, LA Brinton, CS Yang. Cancer Epidemiol Biomarkers Prevent 2001 Nov;10(11):1145-1153. 98.6% of cases versus 29.6% of controls were positive for antibodies to EBV-associated NPC markers, resulting in a 170-fold [one hundred and seventy times!!!] geater risk. Their claim that "Other factors associated with NPC in our study and considered as potential confounders in our analyses include 25 years of cigarette smoking (RR = 1.7; 95% CI = 1.1–2.9)" is bogus, because puny little RRs of 1.7 are easily generated by confounding by great big RRs of 170 - not vice-versa. And likewise for the other purported factors, because stratification by EBV status does not account for important factors such as age at infection or number of subsequent exposures in EBV-positives, nor for false negatives.

Serological markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. YC Cien, JY Chen, MY Liu, HI Yang, MM Hsu, CJ Chen, CS Yang. NEJM 2001 Dec 27;345(26):1877-1882. In a prospective study, the OR for NPC with both markers of EBV was 32.8 (95% CI 7.3-147.2; P=0.003); and with one marker, 4.0 (1.6 to 10.2; P=0.003).

Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. WM Cheng, KH Chan, HL Chen, RX Luo, SP Ng, W Luk, BJ Zheng, MF Ji, JS Liang, JS Sham, DK Wang, YS Zong, MH Ng. Int J Cancer 2002 Feb 1;97(4):489-492. "The risk of the cancer was markedly reduced with odds ratios of 0.009 for 59% of those who had low level of all 3 antibodies. The risk was increased as antibody spectrum broadens and the risk was the highest with an odds ratio of 138 for 0.4% of those who had high levels of all 3 antibodies."

Sinonasal undifferentiated carcinoma and nasopharyngeal-type undifferentiated carcinoma: two clinically, biologically, and histopathically distinct entities. YM Jeng, MT Sung, CL Fang, HY Huang, TL Mao, W Cheng, CH Hsiao. Am J Surg Pathol 2002 Mar;26(3):371-376. All 36 SNUC tumors were negative for EBER-1 by in situ hybridization, while all 13 primary sinonasal nasopharyngeal-type undifferentiated carcinomas were positive for EBER-1 by in situ hybridization.

Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. SF Leung, JS Tam, AT Chan, B Zee, LY Chan, DP Huang, A Van Hasselt, PJ Johnson, YM Lo. Clin Chem 2004 Feb;50(2):339-345. "The sensitivities of EBV DNA and IgA-VCA for diagnosis of NPC were 95% (95% confidence interval, 91-98%) and 81% (73-87%), respectively. The combined marker panel had an overall sensitivity (positive result by either marker) of 99%. The concentrations of both markers showed dependence on cancer stage. The specificities of EBV DNA and IgA-VCA were 98% (96-99%) and 96% (91-98%), respectively. Among 36 healthy family members with false-positive IgA-VCA results, three-fourths had undetectable EBV DNA, whereas the others had increased EBV DNA concentrations that were significantly lower than in NPC patients."

Prevalence and relevance of EBV latency in nasopharyngeal carcinoma in Israel. G Bar-Sela, A Kuten, I Minkov, E Gov-Ari, O Ben-Izhak. J Clin Pathol 2004 Mar;57(3):290-293. 3/5 patients with squamous cell carcinoma were EBV positive and 37/40 non-keratinising and undifferentiated carcinoma cases were positive.

Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea. YK Jeon, BY Lee, JE Kim, SS Lee, CW Kim. Head Neck 2004 Jul;26(7):573-583. "EBER was detected in 55 of 57 cases (96%) of nonkeratinizing carcinoma (NKC) and undifferentiated carcinoma, but in only four of nine cases (44%) of squamous cell carcinoma (SCC)."

Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopharyngeal carcinoma families in Taiwan. XR Yang, S Diehl, R Pfeiffer, CJ Chen, WL Hsu, M Dosemeci, YJ Cheng, B Sun, AM Goldstein, A Hildesheim; Chinese and American Genetic Epidemiology of NPC Study Team. Cancer Epidemiol Biomarkers Prev 2005 Apr;14(4):900-905. "Interestingly, cigarette smoking, especially with longer duration (20 years), seemed inversely related to NPC risk. The patterns observed were similar in analyses restricted to all cases and 501 controls seropositive for antibodies against EBV, except for the attenuated effect of RSA allele." In this study population, ORs for >20 years of cigarette smoking in analysis of all subjects (502 cases and 1942 controls): 0.66 (95% confidence intervals, 0.45-0.96). "Similar results were obtained from analyses using ever/never smoking status, smoking intensity, and pack-years of smoking (data not shown). In addition, in contrast to an earlier report that age at start of smoking was inversely associated with the risk of NPC (32), our data showed no such association (ORage 18-21, 0.92; 95% CI, 0.66-1.28; ORage >22, 1.03; 95% CI, 0.75-1.42). The inversely related effect of cigarette smoking was even stronger in familial case to population control comparisons, suggesting that familial cases smoked less compared with either control groups."

Detection of EBV and HPV in nasopharyngeal carcinoma by in situ hybridization. N Mirzamani, P Salehian, M Farhadi, EA Tehran. Exp Mol Pathol 2006 Dec;81(3):231-234. "EBER-ISH was positive in 19 (95%) of NPCs evaluated and in one metastases from cervical primary, included in this series. Two of 20 NPC (10%) contained HPV 6/11 sequences and two of 20 NPC (10%) contained HPV 16/18 sequences, and combined EBV and HPV infection was detected in 3 of the 20 (15%) patients."

EBV Mechanisms in Nasopharyngeal Carcinoma

Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. G Niedobitek, LS Young, CK Sam, L Brooks, U Prasad and AB Rickinson. Am J Pathol 1992 Apr;140(4):879-887. In 18 undifferentiated NPCs positive for EBV, almost all cases expressed the CDw70 antigen, which in normal tissues is present only in activated lymphoid blasts.

EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. ER Leight, B Sugden. Rev Med Virol 2000 Mar;10(2):83-100.

High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? T Crook, JM Nicholls, L Brooks, J O'Nions, MJ Allday. Oncogene 2000 Jul 13;19(30):3439-3444.

Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. G Decaussin, F Sbih-Lammali, M de Turenne-Tessier, A Bouguermouh, T Ooka. Cancer Res 2000 Oct 1;60(19):5584-5588. Possible role of BARF1 in malignant transformation.

Ethnic differences in the expression of Epstein-Barr virus latent membrane protein-1 mutations in nasopharyngeal carcinoma. M D'Addario, P Chauvin. Mutat Res 2000 Dec 20;457(1-2):69-78.

Association of p53 and BCL-2 expression with Epstein-Barr virus infection in the cancers of head and neck. HJ Yang, YJ Cho, HS Kim, MS Chang, MW Sung, WH Kim. Head Neck 2001 Aug;23(8):629-636.

Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. S Murono, N Raab-Traub, JS Pagano. Cancer Res 2001 Nov 1;61(21):7875-7877. Lead sentence: "Nasopharyngeal cancer is universally associated with EBV infection." This mouse study suggests that anti-viral drugs could prevent and/or treat it.

The role of Epstein-Barr virus-encoded small RNAs (EBERs) in oncogenesis. A Nanbo, K Takada. Rev Med Virol 2002 Sep-Oct;12(5):321-326. "EBERs play a key role in the maintenance of malignant phenotypes of Burkitt's lymphoma (BL) cells... Furthermore, we demonstrated that EBERs confer resistance to interferon (IFN)-alpha-induced apoptosis by inhibition of double-stranded (ds) RNA-activated protein kinase (PKR), which is the key mediator of the antiviral effect of IFN-alpha. These studies provide a new notion that RNA molecules contribute to oncogenesis."

Discrete alterations in the BZLF1 promoter in tumor and non-tumor-associated Epstein-Barr virus. MI Gutierrez, MM Ibrahim, JK Dale, TC Greiner, SE Straus, K Bhatia. J Natl Cancer Inst 2002 Dec 4;94(23):1757-1763.

Epstein-Barr virus in the pathogenesis of NPC. N Raab-Traub. Semin Cancer Biol 2002 Dec;12(6):431-441. Review. "Epstein-Barr virus (EBV) is consistently detected in nasopharyngeal carcinoma (NPC) from regions of high and low incidence. EBV DNA within the tumor is homogeneous with regard to the number of terminal repeats. The detection of a single form of viral DNA suggests that the tumors are clonal proliferations of a single cell that was initially infected with EBV. Specific EBV genes are consistently expressed within the NPC tumors and in early, dysplastic lesions. The viral proteins, latent membrane protein 1 and 2, have profound effects on cellular gene expression and cellular growth, resulting in the highly invasive, malignant growth of NPC tumors. In addition to potential genetic changes, the establishment of a latent, transforming infection in epithelial cells is likely to be a major contributing factor to the development of this tumor."

Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. N Khan, A Hislop, N Gudgeon, M Cobbold, R Khanna, L Nayak, AB Rickinson, PA Moss. J Immunol 2004;173(12):7481-7489. "Interestingly, the effect of age upon EBV-specific responses depends upon donor CMV sero-status. In CMV seropositive donors, the magnitude of the EBV-specific immune response is stable with age, but in CMV seronegative donors, the response to EBV increases significantly with age. By contrast, the influenza-specific CD8 T cell immune response decreases with age, independent of CMV status. The functional activity of the herpesvirus-specific immune response decreases in elderly donors, although the characteristic phenotypes of CMV- and EBV-specific memory populations are retained. This demonstrates that aging is associated with a marked accumulation of CMV-specific CD8 T cells together with a decrease in immediate effector function. Moreover, infection with CMV can reduce prevailing levels of immunity to EBV, another persistent virus. These results suggest that carriage of CMV may be detrimental to the immunocompetent host by suppressing heterologous virus-specific immunity during aging."

Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr Virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. L Zhou, W Jiang, C Ren, Z Yin, X Feng, W Liu, Q Tao, K Yao K. Neoplasia 2005 Sep;7(9):809-815. Hypermethylated RASSF1A was frequently detected in nasopharyngeal carcinoma tissues (82%) and matched tumor-adjacent tissues outside 0.5 cm (75%), but less frequently in tissues outside 1.0 cm (46%).

Epstein-Barr Virus Latent Nuclear Antigens Can Induce Metastasis in a Nude Mouse Model. R Kaul, M Murakami, T Choudhuri, ES Robertson. J Virol 2007 Oct;81(19):10352-10361. "The EBV critical latent antigens EBNA1 and EBNA3C interact with Nm23-H1, a known suppressor of cell migration and tumor metastasis. This interaction is critical for the regulation of downstream cellular genes involved in tumorigenesis and cell migration. The significance of these interactions was determined in nude mice using cancer cells expressing both EBV antigens and Nm23-H1. The EBV antigens promoted the growth of transformed cells in vivo, but their expression was less critical during the later stage of tumor development. The expression of Nm23-H1 affected the growth of cancer cells and suppressed their metastatic potential. This effect was effectively rescued by the expression of both EBV antigens. Interestingly, the prometastatic potential of EBNA3C was greater than that of EBNA1, which triggered a dramatic immune response, as indicated by increased spleen size and development of ascites in the mice. These studies now bridge the expression of the EBV antigens with tumorigenesis and metastasis and widen the range of potential targets for development of therapies for EBV-associated malignancies."

Epstein Barr Virus Nuclear Antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. BG Bajaj, M Murakami, Q Cai, SC Verma, K Lan, ES Robertson. J Virol 2008 Apr;82(8):4082-4090. "In this report, we show that EBNA3C residues 130-190 previously shown to bind to the SCF(Skp2) complex can also strongly associate with the c-Myc oncoprotein. Additionally, the interaction of EBNA3C with c-Myc was mapped to the region of c-Myc that includes the highly conserved Skp2 binding domain. Skp2 has been shown to regulate c-Myc stability and has also been shown to function as a co-activator of transcription for c-Myc target genes. We now show that the EBV latent oncoprotein EBNA3C can stabilize c-Myc and that recruitment of both c-Myc and its cofactor Skp2 to c-Myc dependent promoters can enhance c-Myc dependent transcription. This same region of EBNA3C also recruits and modulates the activity of pRb and p27, both major regulators of the mammalian cell cycle."

Epstein-Barr Virus Immediate Early Protein Zta Co-Opts Mitochondrial Single Stranded DNA Binding Protein To Promote Viral And Inhibit Mitochondrial DNA Replication. A Wiedmer, P Wang, J Zhou, AJ Rennekamp, V Tiranti, M Zeviani, PM Lieberman. J Virol 2008 May;82(9):4647-4655. "Epstein-Barr virus (EBV) lytic replication is initiated by the immediate-early protein Zta.... Mitochondrial DNA synthesis and genome copy number were reduced by Zta-induced EBV lytic replication."

EBV strain differences in NPC

EBV strain variation: geographical distribution and relation to disease state. M Abdel-Hamid, JJ Chen, N Constantine, M Massoud, N Raab-Traub. Virology 1992 Sep;190(1):168-175. "The predominant strains in nasopharyngeal carcinoma (NPC) from regions with elevated incidence were EBV type 1 in southeast Asia and Mediterranean Africa. In Alaskan Eskimos, a distinct variant of EBV type 2 was found in NPC and carcinoma of the parotid gland. This strain contained polymorphisms characteristic of the Asian EBV type 1. The strains prevalent in southeast Asia and Mediterranean Africa were also found in NPC which developed in caucasian Americans. These variants were not detected in lymphomas which developed in central Africa, Mediterranean Africa, or continental United States. These results suggest that distinct EBV strains predominate in geographic areas with elevated incidence of NPC [emphasis added]. The detection of these distinct strains in epithelial tumors from areas of low incidence may reflect an epithelial cell tropism or pathogenicity."

Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. B Neuhierl, R Feederle, W Hammerschmidt, HJ Delecluse. Proc Natl Acad Sci USA 2002 Nov 12;99(23):15036-15041. "We show here that the EBV BALF4 gene product, the glycoprotein gp110, dramatically enhances the ability to infect human cells.... Analysis of several virus isolates showed that the amount of BALF4 present within mature virions markedly differed among these strains.... gp110 constitutes an important virulence factor that determines infection of non-B cells by EBV."

Frequent presence of subtype A virus in Epstein-Barr virus-associated malignancies. SC Peh, LH Kim, S Poppema. Pathology 2002 Oct;34(5):446-450. In 17 Hodgkin's, 14 Burkitt's, 4 T-cell and 3 B-cell non-Hodgkin's lymphomas, "All cases showed presence of type A virus, consistently detected with nested PCR protocol but not with single step PCR. There was no type B virus or mix infections detected."

Potential selection of LMP1 variants in nasopharyngeal carcinoma. RH Edwards, D Sitki-Green, DT Moore, N Raab-Traub. J Virol. 2004 Jan;78(2):868-881. "the strain-specific changes in HLA epitopes in LMP1 may enable its expression in the tumors without recognition by LMP1-specific CTL. In summary, the striking consistent sequence variation of LMP1 strains may contribute to the transformation of epithelial cells in NPC through reduced immune recognition and also through differences in molecular and biologic properties that are yet to be elucidated."

Genomic Sequence Analysis of Epstein-Barr Virus Strain GD1 from a Nasopharyngeal Carcinoma Patient. M-S Zeng, D-J Li, Q-L Liu, L-B Song, M-Z Li, R-H Zhang, X-J Yu, H-M Wang, I Ernberg, and Y-X Zeng. J. Virol. 2005 Dec;79(24):15323-15330. "To date, the only entire Epstein-Barr virus (EBV) genomic sequence available in the database is the prototype B95.8, which was derived from an individual with infectious mononucleosis. A causative link between EBV and nasopharyngeal carcinoma (NPC), a disease with a distinctly high incidence in southern China, has been widely investigated. However, no full-length analysis of any substrain of EBV from this area has been reported. In this study, we analyzed the entire genomic sequence of an EBV strain from a patient with NPC in Guangdong, China.... We detected many sequence variations in GD1 compared to prototypical strain B95.8, including 43 deletion sites, 44 insertion sites, and 1,413 point mutations. Furthermore, we evaluated the frequency of some of these GD1 mutations in Cantonese NPC patients and found them to be highly prevalent. These findings suggest that GD1 is highly representative of the EBV strains isolated from NPC patients in Guangdong, China, an area with the highest incidence of NPC in the world. Furthermore, these findings provide the second full-length sequence analysis of any EBV strain as well as the first full-length sequence analysis of an NPC-derived EBV strain."

Rates

Time and age trends for sinonasal cancer in Connecticut incidence and US mortality rates. GC Roush, MJ Schymura, JM Stevenson, TR Holford. Cancer 1987 Aug 1;60(3):422-428. "For the US mortality rates, from the 1875 to 1950 birth cohorts, there is a decline by more than twofold in men and more than threefold in women."

Incidence and survival rates for young blacks with nasopharyngeal carcinoma in the United States. LM Richey, AF Olshan, J George, CG Shores, AM Zanation, T Cannon, MC Weissler. Arch Otolaryngol Head Neck Surg 2006 Oct;132(10):1035-40. Incidence of nasopharyngeal carcinoma among US black, white, and Asian/Pacific Islanders, diagnosed before age 29, from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) tumor registry. "From 1973 to 2002, incidence rates per 1 million persons, adjusted to the 2000 standard population, for blacks, whites, and Asians younger than 20 years with NPC were 1.61 (n=43), 0.61 (n=99), and 0.95 (n=18), respectively.... From ages 20 to 29 years, rates increased slightly in blacks (1.87) and whites (0.96), while increasing dramatically in Asians (7.18)."

Anti-smoking frauds

Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. TL Vaughan, JA Shapiro, RD Burt, GM Swanson, M Berwick, CF Lynch, JL Lyon. Cancer Epidemiol Biomarkers Prev 1996 Aug;5(8):587-593. This study claimed to find a risk among current smokers of more than 60 pack-years. However, the only EBV-related parameter considered was "diagnosis of infectious mononucleosis," which is associated with EBV infection later in life (whereas EBV infection early in life is characteristic of areas where NPC is endemic). They blow off the importance of EBV in this fashion: "A link between nasopharyngeal carcinoma and infection with the EBV is well documented. However, infection with EBV is a worldwide phenomenon; serological evidence points to its almost ubiquitous presence. Thus, even though the EBV infection appears to be a necessary factor in the development of many nasopharyngeal carcinomas, it is also clear that additional cofactors are required before a malignancy is expressed." This is the standard blow-off of health fascists. The supposed "additional cofactors" of interest to them include human genes but not EBV genes, and "lifestyle" bogeymen which do not include infection with EBV early in life, plus more frequent exposures thereafter.

The end of a fraud: The National Cancer Institute finally admits the truth

The NCI's CancerNet failed to mention Epstein-Barr virus in its discussion of "Paranasal Sinus and Nasal Cavity Cancer," for either health professionals (02/2000) or patients (05/2001). They said only that "Some data indicate that various industrial exposures may be related to cancer of the paranasal sinus and nasal cavity."

To patients, NCI now says that "Ethnic background and exposure to the Epstein-Barr virus can affect the risk of developing nasopharyngeal cancer." But they treat ethnicity and EBV as if they are merely equivalent "risk factors," with no acknowledgment that the first is non-causal while the second is causal. (Nasopharyngeal Cancer (PDQ®): Treatment. General Information About Nasopharyngeal Cancer, Patient Version. Last Modified: 06/21/2005) While to professionals, they say, "Unlike other squamous cell cancers of the head and neck, nasopharyngeal cancer does not appear to be linked to excess use of tobacco and alcohol. Factors thought to predispose to this tumor include Chinese (or Asian) ancestry, Epstein-Barr virus (EBV) exposure, and as yet unknown factors that result in very rare familial clusters." (Nasopharyngeal Cancer (PDQ®): Treatment. General Information. Health Professional Version. Last Modified: 03/22/2006)

The fraud of IARC Monograph 83 (Tobacco smoke and involuntary smoking. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans). IARC Monograph 83. Lyon: International Agency for Research on Cancer; 2004.)

Active smoking: "Although the interpretation of the results is complicated by small sample sizes, the different criteria used for the selection of controls and the problem of control groups with smoking-related diseases, the combined evidence shows an association between tobacco smoking and nasopharyngeal carcinoma in both endemic and non-endemic areas. Infection with Epstein-Barr virus (human herpesvirus 4), a major cause of nasopharyngeal carcinoma worldwide (IARC, 1997), has not been controlled for in any of the available studies [emphasis added](p. 361). However, it is unlikely that confounding by infection with Epstein-Barr virus would explain the observed association between tobacco smoking and risk for nasopharyngeal carcinoma." No justification is offered for this claim, which is unacceptable considering the strong relations of EBV as well as smoking to social class.

Passive smoking (ETS): Likewise, there were no studies of environmental tobacco smoke which considered the role of Epstein-Barr virus infection. The subject of EBV was not even addressed in this section.

Note that Jonathan M. Samet was Chairman of the IARC committee which produced the fraudulent Monograph 83, as well as the Senior Scientific Editor of the 2004 Surgeon General report. He has been a ringleader in every major anti-smoking offensive since the 1980s, including the Surgeon General reports, the corrupt EPA ETS report, and committing perjury in the Minnesota and federal tobacco lawsuits.

The fraud of "The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General" (2006)

In the section on "Nasal Sinus Cavity and Nasopharyngeal Carcinoma" (Chapter 7, Cancer Among Adults from Exposure to Secondhand Smoke, pages 480-482), there is no mention of Epstein-Barr virus (nor is there any mention of it within the entire chapter). They are automatically guilty of scientific fraud for ignoring a known-carcinogenic cause of these cancers, one which is involved in over 90% of cases, and which is known to have strong socioeconomic associations which cause confounding with smoking and passive smoking. They conclude that "The evidence is suggestive but not sufficient to infer a causal relationship between secondhand smoke exposure and a risk of nasal sinus cancer in nonsmokers," and "the evidence is inadequate to infer the presence or absence of a causal relationship between secondhand smoke exposure and a risk of nasopharyngeal cancer among nonsmokers." But they pretend that only "Larger studies with more complete information on secondhand smoke exposure are needed, and "other potential confounders," of which they list "occupational factors" only. Note that the politically-connected charlatan, Jonathan M. Samet, is the lead editor of this report as well.

See also:

EBV and Hodgkin's Disease

Epstein-Barr virus and Hodgkin's disease. H Herbst, G Niedobitek. Int J Clin Lab Res 1993;23(1):13-16. "Seroepidemiological and molecular biological studies have established an association of Hodgkin's disease with Epstein-Barr virus. Recently, Epstein-Barr virus genomes and gene products have been detected in the neoplastic cells of approximately 50% of cases, most notably the latent membrane protein, which has transforming potential."

Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. FE Alexander, RF Jarrett, D Lawrence, AA Armstrong, J Freeland, DA Gokhale, E Kane, GM Taylor, DH Wright, RA Cartwright. Br J Cancer 2000 Mar;82(5):1117-1121. 19/103 tumors were EBV+. History of infectious mononucleosis & Hodgkin's disease, OR= 2.43 (95% CI= 1.10-5.33); history of IM and EBV-positive HD, OR= 9.16 (95% CI= 1.07-78.31).

The correlation of Epstein-Barr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing Hodgkin disease. A Kandil, S Bazarbashi, WA Mourad. Cancer 2001 Jun 1;91(11):1957-1963. EBV expression was seen in 24 (50%) cases.

South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease. KJ Flavell, JP Biddulph, JE Powell, SE Parkes, D Redfern, M Weinreb, P Nelson, JR Mann, LS Young, PG Murray. Br J Cancer 2001 Aug;85(3):350-356. "62% of [55] cases were Epstein-Barr virus-positive... The relative risk of Epstein-Barr virus-positivity showed a gradient with increasing Townsend score; the risk being 7-times higher in the most deprived quartile compared with the least deprived group."

Epstein-Barr virus (EBV) in Chinese pediatric Hodgkin disease: Hodgkin disease in young children is an EBV-related lymphoma. XG Zhou, K Sandvej, PJ Li, XL Ji, QH Yan, XP Zhang, JP Da, SJ Hamilton-Dutoit. Cancer 2001 Sep 15;92(6):1621-1631. In 104 pediatric and 52 adult Chinese HD cases, "EBV was identified in tumor cells in 113 of 156 (72%) HD cases but was more frequent in pediatric cases (93 of 104; 89%) compared with adult cases (20 of 52; 38%) (P < 0.01; chi-square test). EBV was found in 86 out of 91 (95%) cases in children aged 3-10 years and in 7 out of 13 (54%) cases in children aged 11-14 years (P < 0.01; chi-square test).... The authors believe that pediatric HD now should be regarded as a distinctive EBV-related lymphoma."

A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBER-positive Hodgkin's disease. YJ Gan, BI Razzouk, T Su, JW Sixbey. Am J Pathol 2002 Mar;160(3):781-786. "The Epstein-Barr virus (EBV) has been linked to approximately half the cases of Hodgkin’s disease (HD), with virus localized by EBER in situ hybridization to the malignant Reed-Sternberg cell that characteristically makes up less than 1% of the tumor mass. Recent descriptions of relapsed HD, shown to be EBV-positive at initial diagnosis but EBV-negative on reoccurrence, raise the possibility of viral DNA loss during tumor progression in some individuals." 8/24 EBER-negative HD had PCR evidence of defective EBV DNA. "Detection of defective EBV genomes with the potential to disrupt viral gene regulation suggests one mechanism for pathogenic diversity that may also account for loss of prototypic EBV from individual tumor cells."

Epstein-Barr virus in Hodgkin's disease: the example of central Tunisia. S Korbi, M Trimeche, B Sriha, MT Yacoubi, S Hmissa, M Mokni, P Delvenne, J Boniver, S Rammeh. Ann Pathol 2002 Apr;22(2):96-101. EBV early RNA transcripts (EBER) was detected in 70% of 77 cases.

Hematopoietic and lymphatic cancers in relatives of patients with infectious mononucleosis. H Hjalgrim, K Rostgaard, J Askling, M Madsen, HH Storm, CS Rabkin, M Melbye. J Natl Cancer Inst 2002 May 1;94(9):678-681. "The unremarkable risk for Hodgkin's lymphoma in family members of patients with EBV-related infectious mononucleosis indicates that socioeconomic confounding is an unlikely explanation for the association between EBV-related infectious mononucleosis and Hodgkin's lymphoma."

Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis. W Mitarnun, J Pradutkanchana, S Takao, V Saechan, S Suwiwat, T Ishida. J Med Assoc Thai. 2002 May;85(5):552-9. In 58 patients, "EBV internal repeat-1 region (IR-1) in peripheral blood CD3+ cells was detected in 10 of 14 patients (71.5%) with NHL-B, 3 of 8 patients (37.5%) with Hodgkin's disease, 1 of 6 patients (16.7%) with acute leukemia, 4 of 9 patients (44.5%) with SLE, and was not detected in any of the 21 patients with other diseases."

Hodgkin disease in adult and juvenile groups from two different geographic regions in Brazil: characterization of clinicopathologic aspects and relationship with Epstein-Barr virus infection. E De Oliveira, MM Bacchi, ES Abreu, L Niero-Melo, CE Bacchi. Am J Clin Pathol 2002 Jul;118(1):25-30. "HD in Brazilian patients is highly associated with EBV infection."

Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma.
ET Chang, T Zheng, ET Lennette, EG Weir, M Borowitz, RB Mann, D Spiegelman, NE Mueller. J Infect Dis 2004 Jun 15;189(12):2271-2281. "EBV-positive patients were less educated and more likely to have smoked cigarettes and had more prevalent and higher EBV antibody titers, compared with EBV-negative patients."

Phenotype and frequency of Epstein-Barr virus-infected cells in pretreatment blood samples from patients with Hodgkin lymphoma. G Khan, A Lake, L Shield, J Freeland, L Andrew, FE Alexander, R Jackson, PR Taylor, EA McCruden, RF Jarrett. Br J Haematol 2005 May;129(4):511-519. "[T]he frequency of circulating EBV-infected cells was significantly higher (P < 0.001) in pretreatment blood samples from EBV-associated cases when compared with non-EBV-associated cases."

HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. M Niens, RF Jarrett, B Hepkema, IM Nolte, A Diepstra, M Platteel, N Kouprie, CP Delury, A Gallagher, L Visser, S Poppema, GJ te Meerman, A van den Berg. Blood 2007 Nov 1;110(9):3310-3315. 70 patients with EBV+ HL, 31 patients with EBV- HL, and 59 control participants. "HLA-A*01 was significantly overrepresented and HLA-A*02 was significantly underrepresented in patients with EBV+ HL versus controls and patients with EBV- HL. In addition, HLA-A*02 status was determined by immunohistochemistry or HLA-A*02-specific polymerase chain reaction (PCR) on 152 patients with EBV+ HL and 322 patients with EBV- HL. The percentage of HLA-A*02+ patients in the EBV+ HL group (35.5%) was significantly lower than in 6107 general control participants (53.0%) and the EBV- HL group (50.9%)."

Example: Anti-smoking junk

Cigarette smoking and risk of Hodgkin's Disease: A population-based case-control study. NC Briggs, HI Hall, EA Brann, CJ Moriarty, RS Levine. Am J Epidemiol 2002;156(11):1011-1020. "Conditional logistic regression was used to calculate odds ratios and 95% confidence intervals adjusted for age, registry, race/ethnicity, Jewish upbringing, education, and childhood domicile. Compared with never smokers, current smokers had a significantly increased risk of Hodgkin’s disease (odds ratio (OR) = 1.8, 95% confidence interval (CI): 1.3, 2.9)." They simply ignored EBV infection! This is an example of deliberate anti-smoker scientific fraud, under the auspices of the Centers for Disease Control, and published by the coruupt Johns Hopkins Bloomberg School of Public Health. In the year 2002, when no one can legitimately pretend ignorance, they purposely ignore the role of EBV infection, in order to falsely blame by confounding.

See the National Cancer Institute fudge about EBV and HD!

The National Cancer Institute claims that "At this time, the cause or causes of Hodgkin's disease are not known," and insists on calling EBV merely a "risk factor:" "Viruses -- Epstein-Barr virus is an infectious agent that may be associated with an increased chance of getting Hodgkin's disease." They refuse to admit that EBV is CAUSAL, and not merely associated with an increased chance of getting Hodgkin disease. (Risk Factors Associated with Hodgkin's Disease. National Cancer Institute. Posted 06/25/1999, Updated 09/16/2002; viewed 11-30-02, 06-18-05, 10-02-05, and 07-01-06.)

See the American Cancer Society drag its feet about EBV and HD!

The American Cancer Society mirrors the attitude of the NCI in its evasion of the causal role of EBV. "There seems to be a slightly increased rate for Hodgkin's disease in people who have had infectious mononucleosis (sometimes called "mono" for short), an infection caused by the Epstein-Barr virus. However, half of patients with Hodgkin's disease show no evidence of a previous Epstein-Barr virus infection." And they insist that "Even if someone has one or more risk factors for Hodgkin's disease, it is impossible to know for sure how much that risk factor could contribute to causing the cancer. In general, we can say that no major risk factors for Hodgkin's disease have been discovered yet." (What Are the Risk Factors for Hodgkin's Disease? American Cancer Society, as of 10-02-05 and 07-01-06.)

EBV & Other Lymphomas

[Detection of Epstein-Barr virus nucleic acid sequences in non-Hodgkin's lymphoma]. A Sauerbrei, P Wutzler, I Farber, K Wutke, B Brichacek, I Hirsch. Arch Geschwulstforsch 1987;57(6):445-452. EBV nucleic acid and EBNA were found in 5/25 NHLs.

Epstein-Barr virus-associated peripheral T-cell lymphoma of activated CD8 phenotype. IJ Su, KH Lin, CJ Chen, HF Tien, HC Hsieh, DT Lin, JY Chen. Cancer 1990 Dec 15;66(12):2557-2562. Two childhood cases.

Frequent latent Epstein-Barr virus infection of neoplastic T cells and bystander B cells in human immunodeficiency virus-negative European peripheral pleomorphic T-cell lymphomas. P Korbjuhn, I Anagnostopoulos, M Hummel, M Tiemann, F Dallenbach, MR Parwaresch, H Stein. Blood 1993 Jul 1;82(1):217-223. 38 of 81 cases (47%) of PMTCL were positive for EBER by ISH. "By EBER-ISH, the virus was located in the tumor cells in 30 of the 38 EBV-positive cases, with the proportion of the infected cells ranging from 1% to 100%. In 18 of these cases and in the 8 cases without EBV-infected tumor cells, the virus was, respectively, either additionally or exclusively detectable in occasional nonmalignant lymphoid bystander cells."

A Burkitt lymphoma cell line with integrated Epstein-Barr virus at a stable chromosome modification site. NC Popescu, MC Chen, S Simpson, S Solinas, JA DiPaolo. Virology 1993 Jul;195(1):248-251. "Virus insertion into chromosomal DNA caused a stable modification site expressed as a distinctive achromatic region adjacent to the band 2p13. The chromatid lesion at the site of EBV integration involving a recombinogenic and fragile site may have contributed to the development of the NAB-2 BL."

Sinonasal T-cell lymphoma in the differential diagnosis of lethal midline granuloma using in situ hybridization for Epstein-Barr virus RNA. M Dictor, A Cervin, O Kalm, E Rambech. Mod Pathol 1996 Jan;9(1):7-14.

[Two cases of lethal midline granuloma thought to be of natural killer cell origin]. S Tamura, N Yamanaka, T Saito, I Takano, M Hotomi, M Yokoyama. Nippon Jibiinkoka Gakkai Kaiho 1996 Jan;99(1):46-53.

Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. P Kanavaros, J Briere, JF Emile, P Gaulard. Leukemia 1996 Jun;10 Suppl 2:s84-s87. Review.

[Epstein-Barr virus infection in midline malignant reticulosis]. W Liu, J van Gorp, G Li. Zhonghua Zhong, Liu, Za Zhi 1997 Jan;19(1):49-52.

[Clinical characteristics of Epstein-Barr virus-associated natural killer cell lymphoma/leukemia]. K Kawa. Nippon Rinsho 1997 Feb;55(2):424-428.

Natural killer cell lymphoma/leukemia: pathology and treatment. YL Kwong, AC Chan, RH Liang. Hematol Oncol 1997 May;15(2):71-79. Review. "A consistent association with monoclonal Epstein-Barr virus infection in the tumour cell has been observed... Clinically, most cases occur in the nasal area and upper aerodigestive tract. However, occurrence in non-nasal sites such as the skin, gastrointestinal tract and testis is also observed."

Nonnasal lymphoma expressing the natural killer cell marker CD56: A clinicopathologic study of 49 cases of an uncommon agressive neoplasm. KC John, VC Sin, KF Wong, CS Ng, WYW Tsang, CH Chan, MMC Cheung, WH Lau. Blood 1997 Jun 15;89(12):4501-4513. "The nasal-type NK/T-cell lymphoma show distinctive clinicopathologic features and a very strong association with EBV."

Angiocentric T-cell lymphoma presenting as lethal midline granuloma. PY Lee, NJ Freeman, J Khorsand, MA Weinstock. Int J Dermatol 1997 Jun;36(6):419-427.

[Detection of Epstein-Barr virus DNA in malignant lymphomas]. N Kuljic-Kapulica. Vojnosanit Pregl 1997 Sep;54(5):465-468.

Integrated and episomal forms of Epstein-Barr virus (EBV) in EBV associated disease. K Oshima, J Suzumiya, M Kanda, M Kikuchi. Cancer Lett 1998 Jan 9;122(1-2):43-50.

[Epstein-Barr virus infection and expression of T-cell intracellular antigen-1 (TIA-1) in intestinal T-cell lymphoma.] X Ren, W Liu, G Li, F Li, S Zhang. Zhonghua Bing Li Xue Za Zhi 1999 Oct;28(5):348-351. "Intestinal T-cell lymphoma may be an EBV-associated extranodal NK/T cell lymphoma."

Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. I Cuadra-Garcia, GM Prouix, CL Wu, CC Wang, BZ Pilch, NL Harris, JA Ferry. Am J Surg Pathol 1999 Nov;23(11):1356-1369.

Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV-specific nuclear antigen 1. T Yamamoto, Y Nakamura, K Kishimoto, H Takeuchi, M Shirakata, T Mitsuya, K Hirai. Virus Res 1999 Dec 1;65(1):43-55. "Using ISH with improved antisense RNA probe specific to EBNA-1 mRNA, the virus was detected in 19 (59%) of 32 cases, whereas the EBER1 transcript was found in only 15 (47%) of 32 cases by conventional EBER-ISH, resulting in 21 EBV-positive cases (66%) by combining the two methods."

Skin is the frequent site for involvement of peripheral T-cell and natural killer cell lymphomas in Korea. KH Cho, WW Choi, CS Youn, CW Kim, DS Heo. J Dermatol 2000 Aug;27(8):500-507.

Epstein-Barr virus-infected natural killer cell leukemia. K Akashi, S Mizuno. Leuk Lymphoma 2000 Dec;40(1-2):57-66. Review; discussion of hemophagocytic lymphohistiocytosis.

(No title). M Koch, GJ Blatterspiel, G Niedobitek, J Constantinidis. Laryngorhinootologie 2001 Jul;80(7):410-415. Case & review.

Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T cell lymphoma. KI Lei, LY Chan, WY Chan, PJ Johnson, YM Lo. Clin Cancer Res 2002 Jan;8(1):29-34. "Plasma EBV DNA, as measured by real-time quantitative PCR, is a useful tumor marker for diagnosis, disease monitoring, and prediction of outcome in patients with NK/T cell lymphoma."

Primary nasopharyngeal non-Hodgkin lymphoma and its relationship with Epstein-Barr virus infection. B Zhang, Y Zong, J He, B Zhong, S Lin. Chin Med J (Engl) 2003 Jun;116(6):913-917. "The percentages of EBV infection differed among the 3 major immunophenotypes (B cell: 11.36%, 5/44; peripheral T cell: 81.82%, 18/22; NK/T cell: 100%, 7/7)."

Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. TT Kuo, LY Shih, NM Tsang. Int J Surg Pathol 2004 Oct;12(4):375-387. "All 22 cases were positive for EBV by polymerase chain reaction and Epstein-Barr virus early RNA (EBER) in-situ hybridization."

Epstein-Barr viral infection in extranodal lymphoma of the head and neck: correlation with prognosis and response to treatment. AA Bahnassy, AR Zekri, N Asaad, S El-Houssini, HM Khalid, LM Sedky, NM Mokhtar. Histopathology 2006 Apr;48(5):516-528. "The study included 50 PELHN (11 cases in the nose and paranasal sinuses, 11 in the nasopharynx, 13 in the tonsils, seven in the oropharynx and eight in the oral cavity), five reactive lymph nodes, 15 normal nasopharyngeal tissue and 25 throat washes of healthy subjects from Egypt.... EBV was detected in 90% and 70% of the cases using EBER in situ hybridization and PCR, respectively. All cases of nasal type lymphoma were positive for EBV."

Tissue markers of Epstein-Bar virus (EBV) infection in B-cell non-Hodgkin's lymphomas. A Kasprzak, R Spachacz, A Hałoń, M Jeleń, K Stefańska, J Wachowiak, E Trejster, M Zabel. Med Wieku Rozwoj 2006 Jul-Sep;10(3 Pt 1):639-648. Archive tissue material from 26 children and from 27 adults with B-cell NHLs, using immunocytochemical techniques, in situ hybridisation, and PCR. "The detectability and expression of EBV infection were significantly higher in children with B-cell NHLs as compared to adult patients. Expression of EBNA2 and LMP1 and that of EBERs in B-cell NHLs involved mainly cells of CD20(+) phenotype. Positive correlation was confirmed between expression of EBNA2 and LMP1 as well as between expression of the two proteins and EBERs in children with B-cell NHLs. Also in children with B-cell NHLs, type III latency form dominated. In adults the latency forms were more variable. We have demonstrated a novel form of EVB latency with no EBERs expression, noted in children as well as in adults with B-cell NHLs."

[Nasal and pharyngeal non-Hodgkin lymphomas and their relationship with Epstein-Barr virus: a report of 158 cases]. YJ He, XS Jia, K Hasui, EH Wang, AG He. Zhonghua Bing Li Xue Za Zhi 2007 Feb;36(2):94-97. "Among 99 cases studied by EBER-1 in situ hybridization, a positive detection was seen in 70/71 cases (98.6%) of extranodal NK/T cell lymphoma (nasal type), 8/12 cases (66.7%) of T cell lymphoma, and 7/16 cases (43.8%) of B cell lymphoma."

Nasal natural killer/T-cell lymphoma and its association with type "i"/XhoI loss strain Epstein-Barr virus in Chile. ME Cabrera, Y Eizuru, T Itoh, C Koriyama, Y Tashiro, S Ding, S Rey, S Akiba, A Corvalan. J Clin Pathol 2007 Jun;60(6):656-660. 7 out of 9 (78%) of WHO-criteria nasal NK/T-cell lymphomas were positive for EBV.

EBV viral load in tumor tissue is an important prognostic indicator for nasal NK/T-cell lymphoma. PP Hsieh, CL Tung, AB Chan, JB Liao, JS Wang, HH Tseng, HH Su, KC Chang, CC Chang. Am J Clin Pathol 2007 Oct;128(4):579-584. 19 cases. "Patients with a low EBV viral load (<1 copy per cell) more frequently survived for more than 2 years compared with patients with a high EBV viral load (>/=1 copies/cell) (7/7 vs 3/9; P = .014; Fisher exact test). Furthermore, the patients with low EBV viral loads had a better overall survival than patients with high viral loads (50% accumulative survival: not reached vs 4-5 months; Kaplan-Meier survival analysis; P = .049). In contrast, the overall survival of the patients did not correlate with the extent of lesion, age, stage, necrosis, histologic subtypes, CD56 expression, or angiocentric or angiodestructive growth pattern."

Mechanisms

Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr induced lymphoma. SJ Mentzer, J Fingeroth, JJ Reilly, SP Perrine, DV Faller, Blood Cells Mol Dis 1998 Jun;24(2):114-123. "[A]ntiviral therapy with synthetic nucleosides such as ganciclovir are ineffective because the genes that render the virus susceptible to therapy are not expressed in EBV+ lymphomas... Arginine butyrate was not only effective in inducing EBV thymidine kinase transcription, but also acted synergistically with the antiviral agent ganciclovir to inhibit cell proliferation and decrease cell viability."

Interferon Regulatory Factor 7 Is Associated with Epstein-Barr Virus-Transformed Central Nervous System Lymphoma and Has Oncogenic Properties. L Zhang, J Zhang, Q Lambert, CJ Der, L Del Valle, J Miklossy, K Khalili, Y Zhou, JS Pagano. J Virol 2004 Dec;78(23):12987-12995.

The Epstein-Barr Virus-Encoded LMP2A and LMP2B Proteins Promote Epithelial Cell Spreading and Motility. MD Allen, LS Young, CW Dawson. J Virology 2005 Feb;79(3):1789-1802.

LMP1 strain variants: biological and molecular properties. BA Mainou, N Raab-Traub. J Virol 2006 Jul;80(13):6458-6468. "LMP1 can activate a wide array of signaling pathways, including phosphatidylinositol 3-kinase (PI3K)-Akt and NF-kappaB. Six sequence variants of LMP1, termed Alaskan, China 1, China 2, Med+, Med-, and NC, have been identified, and individuals can be infected with multiple variants. The frequencies of detection of these variants differ for various EBV-associated malignancies from different geographic regions.... While all the variants activated the PI3K-Akt signaling pathway to similar extents, the Alaskan, China 1, and Med+ variants had limited binding to the E3 ubiquitin ligase component homologue of Slimb and had slightly enhanced NF-kappaB signaling."

A molecular link between malaria and Epstein-Barr virus reactivation. A Chêne, D Donati, AO Guerreiro-Cacais, V Levitsky, Q Chen, KI Falk, J Orem, F Kironde, M Wahlgren, MT Bejarano. PLoS Pathog 2007 Jun;3(6):e80. "We show that CIDR1alpha binds to the EBV-positive B cell line Akata and increases the number of cells switching to the viral lytic cycle as measured by green fluorescent protein (GFP) expression driven by a lytic promoter. The virus production in CIDR1alpha-exposed cultures was directly proportional to the number of GFP-positive Akata cells (lytic EBV) and to the increased expression of the EBV lytic promoter BZLF1. Furthermore, CIDR1alpha stimulated the production of EBV in peripheral blood mononuclear cells derived from healthy donors and children with BL. Our results suggest that P. falciparum antigens such as CIDR1alpha can directly induce EBV reactivation during malaria infection that may increase the risk of BL development for children living in malaria-endemic areas. To our knowledge, this is the first report to show that a microbial protein can drive a latently infected B cell into EBV replication."

Epstein-Barr Virus Infection of Langerhans Cell Precursors as a Mechanism of Oral Epithelial Entry, Persistence, and Reactivation. DM Walling, AJ Ray, JE Nichols, CM Flaitz, CM Nichols. J Virol 2007 Jul;81(13):7249-7268. "In this study, we present the first evidence demonstrating that EBV latently infects a unique subset of blood-borne mononuclear cells that are direct precursors to Langerhans cells and that EBV both latently and productively infects oral epithelium-resident cells that are likely Langerhans cells. These data form the basis of a proposed new model of EBV transition from blood to oral epithelium in which EBV-infected Langerhans cell precursors serve to transport EBV to the oral epithelium as they migrate and differentiate into oral Langerhans cells. This new model contributes fresh insight into the natural history of EBV infection and the pathogenesis of EBV-associated epithelial disease."

Interactions between EBV and various carcinogens not found

Anti- propagandists have been fear-mongering about so-called "tobacco-specific nitrosamines" since the late 1970s. They deceive the public by calling them "tobacco specific" when they are actually nicotine-specific, and in nonsmokers, ordinary foods such as potatoes and tomatoes can be significant sources of nicotine. Furthermore, after all these years, they have failed to establish any solid body of evidence implicating these substances even in cancer in tobacco users. Laboratory animals are the basis of the supposed carcinogenicity of these substances, but animals are not like humans in that it is easier to cause tumors in animals with chemical carcinogens. It demonstrates the health establishment's monomaniacal obsession with chemical carcinogenesis that it has taken so long to look for possible interactions with infection, which in these studies with EBV have turned out negative.

Evaluation of the effect of smokeless tobacco purified products and extracts on latent Epstein-Barr virus. HB Jenson, P Heard, MP Moyer. Toxicology 1999 Mar 1;133(1):35-42. "There does not appear to be an in vitro effect of smokeless-tobacco constituents on EBV-infected lymphocytes that may contribute to the development of oral cancers."

Effects of smokeless tobacco and tumor promoters on cell population growth and apoptosis of B lymphocytes infected with epstein-barr virus types 1 and 2. HB Jenson, J Baillargeon, P Heard, MP Moyer. Toxicol Appl Pharmacol 1999 Oct 15;160(2):171-182. "The absence of significant effects with NNK and NNN suggest that these properties reside with other compounds present in tobacco extracts." The property in point is cell lysis, meaning death, which aborts carcinogenesis.

See Also:

cast 04-13-08